Skip to main content
. 2017 Mar 14;5:ISCB Comm J-2927. Originally published 2016 Dec 28. [Version 2] doi: 10.12688/f1000research.10529.2

Figure 3. Examples of drugs for which transcriptomic markers predict their cell line sensitivity with better precision than that of single-gene markers on the test set.

Figure 3.

( A) Test set precision obtained by the AZD628-BRAF marker is moderate (PR=0.50) despite being a strong drug-gene association (P=3∙10 -15). By contrast, the multi-gene marker for AZD628 achieves a substantially higher precision (PR=0.88). ( B) The sunitinib-Kinase Insert Domain Receptor (KDR) association (P=0.0002) offers no precision in the test set, since none of the test cell lines harbour mutations in the KDR gene. By contrast, the transcriptomic marker achieves a much higher precision (PR=0.75). Interestingly, both multi-gene markers achieve much better recall (RC=0.37 for AZD628 and RC=0.75 for sunitinib) than their corresponding single-gene markers (RC=0.05 and RC=0.00), which means that a substantially higher proportion of sensitive cell lines are correctly predicted as sensitive.